Literature DB >> 18321903

Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness.

Andrew M Luks1, Erik R Swenson.   

Abstract

With increasing numbers of people traveling to high altitude for work or pleasure, there is a reasonable chance that many of these travelers have preexisting medical conditions or are receiving various medications at the time of their sojourn. As with all travelers to high altitude, they are at risk for altitude illnesses such as acute mountain sickness, high-altitude cerebral edema, and high-altitude pulmonary edema. While there are clear recommendations for pharmacologic measures to prevent or treat these illnesses, these recommendations are oriented toward healthy individuals and do not take into account the presence of preexisting medical conditions. In this review, we consider how the choice and dose of the medications used in the management of altitude illness-acetazolamide, dexamethasone, nifedipine, tadalafil, sildenafil, and salmeterol-are affected by a patient's underlying medical conditions. We discuss the indications and current dosing recommendations for individuals without underlying disease, and then consider how drug selection or dosing regimens will be affected by the presence of renal insufficiency, hepatic insufficiency, other important medical conditions, and the potential for serious drug interactions. We include comments about interactions with antimalarial medications and antibiotics used in the treatment of traveler's diarrhea, as well as the safety of use during pregnancy. By giving these issues adequate consideration, clinicians can increase the chances that properly evaluated patients with underlying medical conditions will enjoy a safe trip to high altitude.

Entities:  

Mesh:

Year:  2008        PMID: 18321903     DOI: 10.1378/chest.07-1417

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Dexamethasone blocks the systemic inflammation of alveolar hypoxia at several sites in the inflammatory cascade.

Authors:  Jie Chao; Zachary Viets; Paula Donham; John G Wood; Norberto C Gonzalez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-18       Impact factor: 4.733

2.  Pulmonary vasodilation by acetazolamide during hypoxia: impact of methyl-group substitutions and administration route in conscious, spontaneously breathing dogs.

Authors:  Philipp A Pickerodt; Roland C Francis; Claudia Höhne; Friederike Neubert; Stella Telalbasic; Willehad Boemke; Erik R Swenson
Journal:  J Appl Physiol (1985)       Date:  2014-01-30

Review 3.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

4.  Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude.

Authors:  Xiang-Yang Li; Yong-Nian Liu; Xue-Jun Wang; Jun-Bo Zhu; Ming Yuan; Yong-Ping Li; Yong-Fang Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03-30       Impact factor: 2.441

5.  Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.

Authors:  Daniel Molano Franco; Víctor H Nieto Estrada; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2019-04-23

Review 6.  [Effects of acute altitude exposure: which altitude can be tolerated?].

Authors:  Martin Burtscher
Journal:  Wien Med Wochenschr       Date:  2010-07

Review 7.  Short-term responses of the kidney to high altitude in mountain climbers.

Authors:  Alexander S Goldfarb-Rumyantzev; Seth L Alper
Journal:  Nephrol Dial Transplant       Date:  2013-03-22       Impact factor: 5.992

8.  An Approach to Children with Pulmonary Edema at High Altitude.

Authors:  Deborah R Liptzin; Steven H Abman; Ann Giesenhagen; D Dunbar Ivy
Journal:  High Alt Med Biol       Date:  2018-02-22       Impact factor: 1.981

Review 9.  Ear, nose, and throat effects of high altitude.

Authors:  Cemal Cingi; Alper Nabi Erkan; Gerhard Rettinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-06-24       Impact factor: 2.503

10.  Return to activity at altitude after high-altitude illness.

Authors:  Kevin Deweber; Keith Scorza
Journal:  Sports Health       Date:  2010-07       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.